Figure 2From: Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis Distribution of treatment response rates for patients with malignant glioma in all published data. The mean response rate was 23.3 ± 22.3% in 326 studies.Back to article page